Xgeva (denosumab)

Xgeva (Denosumab) is a fully human monoclonal antibody designed to target and inhibit receptor activator of nuclear factor kappa-B ligand (RANKL), a key protein responsible for the formation, function, and survival of osteoclasts—the cells that break down bone tissue. By blocking RANKL, Xgeva helps reduce bone destruction, preserve bone strength, and prevent complications associated with bone metastases and certain bone disorders.

Xgeva is widely used to prevent skeletal-related events, such as fractures, spinal cord compression, and the need for radiation or surgery to bone, in patients with solid tumors that have metastasized to the bone. It is also indicated for the treatment of giant cell tumor of bone in specific patient populations and for the management of hypercalcemia of malignancy that is resistant to bisphosphonate therapy.

Administered as a subcutaneous injection under the supervision of healthcare professionals, Xgeva has demonstrated significant clinical benefits in reducing bone complications and improving quality of life for patients affected by cancer-related bone disease. Its targeted mechanism of action provides effective protection against bone loss while supporting long-term skeletal health.

As an innovative bone-targeted therapy, Xgeva represents an important advancement in supportive oncology care. Its proven efficacy, targeted action, and broad clinical applications continue to make it an essential treatment option for managing bone complications associated with cancer and improving patient outcomes worldwide.